Atopic Disease Prevention

Atopic Diseases Treatment

In addition to prevention, Siolta has plans to investigate the effectiveness of STMC-103H in treating atopic diseases, including atopic dermatitis, food allergy, and asthma.

A New Class of Medicines

The current standard of care treatments such as antihistamines, steroids, bronchodilators, and biologics, target the downstream inflammation that results from an inappropriate immune response. In contrast, Siolta Therapeutic’s microbiome-based approach towards atopic diseases aims to prevent the initiation of the immune dysfunction cascade, thus preventing allergic disease before it starts. Our preclinical proof of concept studies provide evidence that oral supplementation with STMC-103H has the potential to alter the gut microbiome, reprogram metabolism, reduce immune activation, and thus protect against allergic inflammation

STMC-105 – Prevention of Recurrent Bacterial Vaginosis (BV)

Bacterial vaginosis is one of the most common women’s health conditions, impacting up to 50% of women globally.  Bacterial vaginosis is associated with disruptions to the protective community of bacteria in the vaginal tract and the colonization by opportunistic microbes.   Standard of care treatments using antibiotics can be effective at treating bacterial vaginosis by reducing microbial burden, however these approaches fail to address the critical need to establish a stable and protective microbiota for long-term vaginal health and prevention of disease recurrence. To address this unmet need, Siolta Therapeutics is applying deep characterization of metabolic crosstalk and functional ecology within vaginal microbial communities to develop the microbial consortium STMC-105. This synergistic multi-strain LBP is designed to provide maximum resilience from vaginal microbiota community disruption, opportunistic pathobiont colonization, and recurrence of symptomatic bacterial vaginosis.

STMC-106 – Prevention of  Necrotizing Enterocolitis (NEC)

Necrotizing enterocolitis is a serious inflammatory disease of the bowel and the most common single cause of sepsis and death in preterm infants. NEC occurs primarily in infants born before 32 weeks gestation, with overall incidence inversely proportional to gestational age. Several additional risk factors for NEC, including initiation of enteral feeding, antibiotic treatment, and acid suppression treatment, are key factors influencing the development of the preterm infant gut microbiome. Observations of abnormal infant gut microbiome development in preterm infants, with increased colonization by opportunistic pathobionts, strongly supports the role of the gut microbiome in the pathogenesis of NEC. Siolta Therapeutics is leveraging our proprietary Precision Symbiotic Platform to develop STMC-106, a mixed-species LBP designed to fortify the preterm infant gut by instilling protective microbe-epithelial signaling and metabolic activity that reduces pathobiont colonization and restores intestinal epithelial barrier function. STMC-106 will simultaneously leverage multiple mechanisms of action to reduce the development of NEC in high-risk preterm infants.